Inter-species interactions alter antibiotic efficacy in bacterial communities
1.Filkins LM, O’Toole GA. Cystic fibrosis lung infections: polymicrobial, complex, and hard to treat. PLoS Pathog. 2015;11:e1005258.PubMed
PubMed Central
Article
CAS
Google Scholar
2.Paterson IK, Hoyle A, Ochoa G, Baker-Austin C, Taylor NGH. Optimising antibiotic usage to treat bacterial infections. Sci Rep. 2016;6:37853.CAS
PubMed
PubMed Central
Article
Google Scholar
3.Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother. 2001;48:5–16.CAS
PubMed
Article
Google Scholar
4.Brook I. Inoculum effect. Rev Infect Dis. 1989;11:361–8.CAS
PubMed
Article
Google Scholar
5.Karslake J, Maltas J, Brumm P, Wood KB. Population density modulates drug inhibition and gives rise to potential bistability of treatment outcomes for bacterial infections. PLOS Comput Biol. 2016;12:e1005098.PubMed
PubMed Central
Article
CAS
Google Scholar
6.Udekwu KI, Parrish N, Ankomah P, Baquero F, Levin BR. Functional relationship between bacterial cell density and the efficacy of antibiotics. J Antimicrob Chemother. 2009;63:745–57.CAS
PubMed
PubMed Central
Article
Google Scholar
7.Sweeney E, Sabnis A, Edwards AM, Harrison F. Effect of host-mimicking medium and biofilm growth on the ability of colistin to kill Pseudomonas aeruginosa. Microbiology. 2020;166:1171–80.CAS
PubMed
PubMed Central
Article
Google Scholar
8.Walters MC, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother. 2003;47:317–23.CAS
PubMed
PubMed Central
Article
Google Scholar
9.Nguyen D, Joshi-Datar A, Lepine F, Bauerle E, Olakanmi O, Beer K, et al. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science. 2011;334:982–6.CAS
PubMed
PubMed Central
Article
Google Scholar
10.Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35:322–32.PubMed
Article
CAS
Google Scholar
11.Olsen I. Biofilm-specific antibiotic tolerance and resistance. Eur J Clin Microbiol Infect Dis. 2015;34:877–86.CAS
PubMed
Article
Google Scholar
12.Macia MD, Rojo-Molinero E, Oliver A. Antimicrobial susceptibility testing in biofilm-growing bacteria. Clin Microbiol Infect. 2014;20:981–90.CAS
PubMed
Article
Google Scholar
13.Thieme L, Hartung A, Tramm K, Klinger-Strobel M, Jandt KD, Makarewicz O, et al. MBEC versus MBIC: the lack of differentiation between biofilm reducing and inhibitory effects as a current problem in biofilm methodology. Biol Proced Online. 2019;21:18.PubMed
PubMed Central
Article
CAS
Google Scholar
14.Bottery MJ, Pitchford JW, Friman V-P. Ecology and evolution of antimicrobial resistance in bacterial communities. ISME J. 2021;15:939–48.PubMed
Article
Google Scholar
15.Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest. 2003;123:1495–502.CAS
PubMed
Article
Google Scholar
16.Radlinski L, Conlon B. Antibiotic efficacy in the complex infection environment. Curr Opin MicrobioL 2018;42:19–24.CAS
PubMed
Article
Google Scholar
17.Vos MGJ, de, Zagorski M, McNally A, Bollenbach T. Interaction networks, ecological stability, and collective antibiotic tolerance in polymicrobial infections. PNAS. 2017;114:10666–71.PubMed
PubMed Central
Article
CAS
Google Scholar
18.Adamowicz EM, Flynn J, Hunter RC, Harcombe WR. Cross-feeding modulates antibiotic tolerance in bacterial communities. ISME J. 2018;12:2723–35.CAS
PubMed
PubMed Central
Article
Google Scholar
19.Aranda-Díaz A, Obadia B, Dodge R, Thomsen T, Hallberg ZF, Güvener ZT, et al. Bacterial interspecies interactions modulate pH-mediated antibiotic tolerance. eLife. 2020;9:e51493.PubMed
PubMed Central
Article
Google Scholar
20.Vega NM, Gore J. Collective antibiotic resistance: mechanisms and implications. Curr Opin Microbiol. 2014;21:28–34.CAS
PubMed
PubMed Central
Article
Google Scholar
21.Beaudoin T, Yau YCW, Stapleton PJ, Gong Y, Wang PW, Guttman DS, et al. Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance. NPJ Biofilms Microbiomes. 2017;3:25.CAS
PubMed
PubMed Central
Article
Google Scholar
22.Orazi G, O’Toole GA. Pseudomonas aeruginosa alters Staphylococcus aureus sensitivity to vancomycin in a biofilm model of cystic fibrosis infection. mBio. 2017;8:e00873–17.PubMed
PubMed Central
Article
Google Scholar
23.Sorg RA, Lin L, Doorn GS, van, Sorg M, Olson J, Nizet V, et al. Collective resistance in microbial communities by intracellular antibiotic deactivation. PLOS Biol. 2016;14:e2000631.PubMed
PubMed Central
Article
CAS
Google Scholar
24.Perlin MH, Clark DR, McKenzie C, Patel H, Jackson N, Kormanik C, et al. Protection of Salmonella by ampicillin-resistant Escherichia coli in the presence of otherwise lethal drug concentrations. Proc R Soc B. 2009;276:3759–68.CAS
PubMed
PubMed Central
Article
Google Scholar
25.Flynn JM, Cameron LC, Wiggen TD, Dunitz JM, Harcombe WR, Hunter RC. Disruption of cross-feeding inhibits pathogen growth in the sputa of patients with cystic fibrosis. mSphere. 2020;5:e00343–20.CAS
PubMed
PubMed Central
Article
Google Scholar
26.Gurney J, Brown SP, Kaltz O, Hochberg ME. Steering phages to combat bacterial pathogens. Trends Microbiol. 2020;28:85–94.CAS
PubMed
Article
Google Scholar
27.Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, et al. Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections. Clin Infect Dis. 2019;69:1812–6.CAS
PubMed
Article
Google Scholar
28.Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, et al. Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: a systematic review. J Cyst Fibros. 2019;18:236–43.CAS
PubMed
Article
Google Scholar
29.Raghuvanshi R, Vasco K, Vázquez-Baeza Y, Jiang L, Morton JT, Li D, et al. High-resolution longitudinal dynamics of the cystic fibrosis sputum microbiome and metabolome through antibiotic therapy. mSystems. 2020;5:e00292–20.CAS
PubMed
PubMed Central
Article
Google Scholar
30.Cystic Fibrosis Trust. UK cystic fibrosis registry annual data report 2019. 2020. [online] Available at: https://www.cysticfibrosis.org.uk/sites/default/files/2020-12/2019%20Registry%20Annual%20Data%20report_Sep%202020.pdf [Accessed 5 June 2021].31.Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001;138:699–704.CAS
PubMed
Article
PubMed Central
Google Scholar
32.Sánchez MB. Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia. Front Microbiol. 2015;6:658.PubMed
PubMed Central
Article
Google Scholar
33.Salsgiver EL, Fink AK, Knapp EA, LiPuma JJ, Olivier KN, Marshall BC, et al. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis. Chest. 2016;149:390–400.PubMed
PubMed Central
Article
Google Scholar
34.Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis. 2009. [online] Available at: https://www.cysticfibrosis.org.uk/sites/default/files/2020-11/Anitbiotic%20Treatment.pdf [Accessed 7 June 2021].35.Denton M, Todd NJ, Littlewood JM. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 1996;15:402–5.CAS
PubMed
Article
Google Scholar
36.Esposito A, Pompilio A, Bettua C, Crocetta V, Giacobazzi E, Fiscarelli E, et al. Evolution of Stenotrophomonas maltophilia in cystic fibrosis lung over chronic infection: a genomic and phenotypic population study. Front Microbiol. 2017;8:1590.PubMed
PubMed Central
Article
Google Scholar
37.Pompilio A, Crocetta V, De Nicola S, Verginelli F, Fiscarelli E, Di Bonaventura G. Cooperative pathogenicity in cystic fibrosis: Stenotrophomonas maltophilia modulates Pseudomonas aeruginosa virulence in mixed biofilm. Front Microbiol. 2015;6:951.PubMed
PubMed Central
Article
Google Scholar
38.Dalbøge CS, Hansen CR, Pressler T, Høiby N, Johansen HK. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. J Cyst Fibros. 2011;10:318–25.PubMed
Article
Google Scholar
39.Okazaki A, Avison MB. Induction of L1 and L2 β-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator. Antimicrob Agents Chemother. 2008;52:1525–8.CAS
PubMed
PubMed Central
Article
Google Scholar
40.Yurtsev EA, Chao HX, Datta MS, Artemova T, Gore J. Bacterial cheating drives the population dynamics of cooperative antibiotic resistance plasmids. Mol Syst Biol. 2013;9:683.CAS
PubMed
PubMed Central
Article
Google Scholar
41.Bottery MJ, Wood AJ, Brockhurst MA. Selective conditions for a multidrug resistance plasmid depend on the sociality of antibiotic resistance. Antimicrob Agents Chemother. 2016;60:2524–7.CAS
PubMed
PubMed Central
Article
Google Scholar
42.Palmer KL, Aye LM, Whiteley M. Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum. J Bacteriol. 2007;189:8079–87.CAS
PubMed
PubMed Central
Article
Google Scholar
43.Artemova T, Gerardin Y, Dudley C, Vega NM, Gore J. Isolated cell behavior drives the evolution of antibiotic resistance. Mol Syst Biol. 2015;11:822.PubMed
PubMed Central
Article
CAS
Google Scholar
44.Harrison E, Wood AJ, Dytham C, Pitchford JW, Truman J, Spiers A, et al. Bacteriophages limit the existence conditions for conjugative plasmids. mBio. 2015;6:e00586–15.PubMed
PubMed Central
Google Scholar
45.Hall JPJ, Wood AJ, Harrison E, Brockhurst MA. Source–sink plasmid transfer dynamics maintain gene mobility in soil bacterial communities. PNAS. 2016;113:8260–5.CAS
PubMed
PubMed Central
Article
Google Scholar
46.Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, Levin BR. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother. 2004;48:3670–6.CAS
PubMed
PubMed Central
Article
Google Scholar
47.Yu G, Baeder DY, Regoes RR, Rolff J. Predicting drug resistance evolution: insights from antimicrobial peptides and antibiotics. Proc R Soc B. 2018;285:20172687.PubMed
PubMed Central
Article
CAS
Google Scholar
48.Zhanel GG, Simor AE, Vercaigne L, Mandell L. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can J Infect Dis. 1998;9:215–28.CAS
PubMed
PubMed Central
Google Scholar
49.Gould VC, Okazaki A, Avison MB. β-Lactam resistance and β-lactamase expression in clinical Stenotrophomonas maltophilia isolates having defined phylogenetic relationships. J Antimicrob Chemother. 2006;57:199–203.CAS
PubMed
Article
Google Scholar
50.European Cystic Fibrosis Society Patient Registry. ECFS patient registry annual data report 2018. 2020. [online] Available at: https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Report_2018_v1.4.pdf [Accessed 7 June 2021].51.Radlinski L, Rowe SE, Kartchner LB, Maile R, Cairns BA, Vitko NP, et al. Pseudomonas aeruginosa exoproducts determine antibiotic efficacy against Staphylococcus aureus. PLoS Biol. 2017;15:e2003981.PubMed
PubMed Central
Article
CAS
Google Scholar
52.Harrison FY. Microbial ecology of the cystic fibrosis lung. Microbiology. 2007;153:917–23.CAS
PubMed
Article
Google Scholar
53.Keel RA, Sutherland CA, Crandon JL, Nicolau DP. Stability of doripenem, imipenem and meropenem at elevated room temperatures. Int J Antimicrob Agents. 2011;37:184–5.CAS
PubMed
Article
Google Scholar
54.Okazaki A, Avison MB. Aph(3′)-IIc, an Aminoglycoside resistance determinant from Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2007;51:359–60.CAS
PubMed
Article
Google Scholar
55.Li X-Z, Zhang L, McKay GA, Poole K. Role of the acetyltransferase AAC(6′)-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J Antimicrob Chemother. 2003;51:803–11.CAS
PubMed
Article
Google Scholar
56.Frost I, Smith WPJ, Mitri S, Millan AS, Davit Y, Osborne JM, et al. Cooperation, competition and antibiotic resistance in bacterial colonies. ISME J. 2018;12:1582–93.CAS
PubMed
PubMed Central
Article
Google Scholar
57.Yin C, Yang W, Meng J, Lv Y, Wang J, Huang B. Co-infection of Pseudomonas aeruginosa and Stenotrophomonas maltophilia in hospitalised pneumonia patients has a synergic and significant impact on clinical outcomes. Eur J Clin Microbiol Infect Dis. 2017;36:2231–5.CAS
PubMed
Article
Google Scholar
58.Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I, et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med. 2011;183:635–40.PubMed
Article
Google Scholar
59.Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax. 2004;59:955–9.CAS
PubMed
PubMed Central
Article
Google Scholar
60.Mojica MF, Ouellette CP, Leber A, Becknell MB, Ardura MI, Perez F, et al. Successful treatment of bloodstream infection due to metallo-β-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient. Antimicrob Agents Chemother. 2016;60:5130–4.CAS
PubMed
PubMed Central
Article
Google Scholar
61.McCutcheon JG, Dennis JJ. The potential of phage therapy against the emerging opportunistic pathogen Stenotrophomonas maltophilia. Viruses. 2021;13:1057.CAS
PubMed
PubMed Central
Article
Google Scholar
62.Rossi E, La Rosa R, Bartell JA, Marvig RL, Haagensen JAJ, Sommer LM, et al. Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis. Nat Rev Microbiol. 2021;19:331–42.CAS
PubMed
Article
Google Scholar
63.Davies EV, James CE, Brockhurst MA, Winstanley C. Evolutionary diversification of Pseudomonas aeruginosa in an artificial sputum model. BMC Microbiol. 2017;17:3.PubMed
PubMed Central
Article
CAS
Google Scholar
64.Bara JJ, Matson Z, Remold SK. Life in the cystic fibrosis upper respiratory tract influences competitive ability of the opportunistic pathogen Pseudomonas aeruginosa. R Soc Open Sci. 2018;5:180623.PubMed
PubMed Central
Article
CAS
Google Scholar
65.Bartell JA, Sommer LM, Haagensen JAJ, Loch A, Espinosa R, Molin S, et al. Evolutionary highways to persistent bacterial infection. Nat Commun. 2019;10:629.CAS
PubMed
PubMed Central
Article
Google Scholar
66.Estrela S, Brown SP. Community interactions and spatial structure shape selection on antibiotic resistant lineages. PLOS Comput Biol. 2018;14:e1006179.PubMed
PubMed Central
Article
CAS
Google Scholar
67.McNally L, Bernardy E, Thomas J, Kalziqi A, Pentz J, Brown SP, et al. Killing by Type VI secretion drives genetic phase separation and correlates with increased cooperation. Nat Commun. 2017;8:14371.CAS
PubMed
PubMed Central
Article
Google Scholar
68.Burmølle M, Webb JS, Rao D, Hansen LH, Sørensen SJ, Kjelleberg S. Enhanced biofilm formation and increased resistance to antimicrobial agents and bacterial invasion are caused by synergistic interactions in multispecies biofilms. Appl Environ Microbiol. 2006;72:3916–23.PubMed
PubMed Central
Article
CAS
Google Scholar
69.Willner D, Haynes MR, Furlan M, Schmieder R, Lim YW, Rainey PB, et al. Spatial distribution of microbial communities in the cystic fibrosis lung. ISME J. 2012;6:471–4.CAS
PubMed
Article
Google Scholar
70.Turner KH, Wessel AK, Palmer GC, Murray JL, Whiteley M. Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum. PNAS. 2015;112:4110–5.CAS
PubMed
PubMed Central
Article
Google Scholar
71.Kirchner S, Fothergill JL, Wright EA, James CE, Mowat E, Winstanley C. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung. J Vis Exp. 2012;64:e3857.
Google Scholar
72.Harrison F, Diggle SP. An ex vivo lung model to study bronchioles infected with Pseudomonas aeruginosa biofilms. Microbiology. 2016;162:1755–60.CAS
PubMed
Article
PubMed Central
Google Scholar
73.Harrington NE, Sweeney E, Harrison F. Building a better biofilm – formation of in vivo-like biofilm structures by Pseudomonas aeruginosa in a porcine model of cystic fibrosis lung infection. Biofilm. 2020;2:100024.PubMed
PubMed Central
Article
Google Scholar
74.Bricio-Moreno L, Sheridan VH, Goodhead I, Armstrong S, Wong JKL, Waters EM, et al. Evolutionary trade-offs associated with loss of PmrB function in host-adapted Pseudomonas aeruginosa. Nat Commun. 2018;9:2635.PubMed
PubMed Central
Article
CAS
Google Scholar
75.Castellani S, Di Gioia S, di Toma L, Conese M. Human cellular models for the investigation of lung inflammation and mucus production in cystic fibrosis. Anal Cell Pathol. 2018;2018:3839803.Article
CAS
Google Scholar
76.Levin-Reisman I, Ronin I, Gefen O, Braniss I, Shoresh N, Balaban NQ. Antibiotic tolerance facilitates the evolution of resistance. Science. 2017;355:826–30.CAS
PubMed
Article
PubMed Central
Google Scholar
77.Wistrand-Yuen E, Knopp M, Hjort K, Koskiniemi S, Berg OG, Andersson DI. Evolution of high-level resistance during low-level antibiotic exposure. Nat Commun. 2018;9:1599.PubMed
PubMed Central
Article
CAS
Google Scholar
78.Choi K-H, Schweizer HP. mini-Tn7 insertion in bacteria with single attTn7 sites: example Pseudomonas aeruginosa. Nat Protoc. 2006;1:153–61.CAS
PubMed
Article
PubMed Central
Google Scholar
79.Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and Its applications to single-cell Sequencing. J Comput Biol. 2012;19:455–77.CAS
PubMed
PubMed Central
Article
Google Scholar
80.Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30:2068–9.CAS
Article
Google Scholar
81.Onoue Y, Mori M. Amino acid requirements for the growth and enterotoxin production by Staphylococcus aureus in chemically defined media. Int J Food Microbiol. 1997;36:77–82.CAS
PubMed
Article
Google Scholar
82.Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018;35:1547–9.CAS
PubMed
PubMed Central
Article
Google Scholar
83.Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol. 2010;59:307–21.CAS
PubMed
Article
Google Scholar
84.Lefort V, Longueville J-E, Gascuel O. SMS: smart model selection in PhyML. Mol Biol Evol. 2017;34:2422–4.CAS
PubMed
PubMed Central
Article
Google Scholar
85.Kuznetsov A, Bollin CJ. NCBI Genome Workbench: desktop software for comparative genomics, visualization, and GenBank data submission. Methods Mol Biol. 2021;2231:261–95.CAS
PubMed
Article
Google Scholar
86.Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–60.CAS
PubMed
PubMed Central
Article
Google Scholar More